Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Sales and Divestitures (2017 - 2022)

Historic Gains from Sales and Divestitures for Arcus Biosciences (RCUS) over the last 6 years, with Q4 2022 value amounting to $500000.0.

  • Arcus Biosciences' Gains from Sales and Divestitures rose 3082.74% to $500000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $500000.0, marking a year-over-year increase of 3082.74%. This contributed to the annual value of $500000.0 for FY2022, which is 3082.74% up from last year.
  • According to the latest figures from Q4 2022, Arcus Biosciences' Gains from Sales and Divestitures is $500000.0, which was up 3082.74% from $382183.0 recorded in Q4 2021.
  • Arcus Biosciences' 5-year Gains from Sales and Divestitures high stood at $500000.0 for Q4 2022, and its period low was $6250.0 during Q4 2020.
  • Over the past 5 years, Arcus Biosciences' median Gains from Sales and Divestitures value was $372774.0 (recorded in 2019), while the average stood at $255225.0.
  • Per our database at Business Quant, Arcus Biosciences' Gains from Sales and Divestitures crashed by 9832.34% in 2020 and then skyrocketed by 601492.8% in 2021.
  • Quarter analysis of 5 years shows Arcus Biosciences' Gains from Sales and Divestitures stood at $14918.0 in 2018, then skyrocketed by 2398.82% to $372774.0 in 2019, then crashed by 98.32% to $6250.0 in 2020, then skyrocketed by 6014.93% to $382183.0 in 2021, then surged by 30.83% to $500000.0 in 2022.
  • Its last three reported values are $500000.0 in Q4 2022, $382183.0 for Q4 2021, and $6250.0 during Q4 2020.